Mariagrazia Rossi

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Survival After Invasive or Conservative Management of Stable Coronary Disease

Judith S. Hochman, Rebecca Anthopolos, Harmony R. Reynolds et al. · Circulation · 2022 · 147 citations · Full text

Medicine, Cardiology, Internal Medicine +13

The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis

Francesco Motolese, Mariagrazia Rossi, Giuliano Albergo et al. · Frontiers in Neurology · 2020 · 90 citations · Full text

Medicine, Psychiatry, Health Psychology +12

Parkinson's Disease Remote Patient Monitoring During the COVID-19 Lockdown

Francesco Motolese, Alessandro Magliozzi, Fiorella Puttini et al. · Frontiers in Neurology · 2020 · 79 citations · Full text

Medicine, Health Informatics, Neurology +15

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies

Fioravante Capone, Matteo Lucchini, Elisabetta Ferraro et al. · Neurotherapeutics · 2021 · 46 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16